Rid­ing on ear­ly can­cer de­tec­tion fren­zy, Freenome scores $270M to push liq­uid biop­sy tech be­yond col­orec­tal can­cer

Covid-19 and its man­i­fold sec­ondary ef­fects have forced many biotech com­pa­nies to adapt their clin­i­cal tri­als to the new nor­mal. For Gabe Otte, it sim­ply re­in­forced the im­por­tance of the tweaks Freenome was al­ready plan­ning with the piv­otal study of its blood test for col­orec­tal can­cer.

While an av­er­age of 800,000 to a mil­lion Amer­i­cans would get screened every month in the pre-pan­dem­ic times — around 5,000 to 7,000 of whom would be di­ag­nosed with can­cer and pro­ceed to treat­ment — many would-be can­cer pa­tients are now not get­ting found.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER